Clinical trials
Completed Glaucoma, Open-Angle trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
573 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 4 |
| 2001 | 5 |
| 2002 | 4 |
| 2003 | 9 |
| 2004 | 6 |
| 2005 | 19 |
| 2006 | 20 |
| 2007 | 26 |
| 2008 | 28 |
| 2009 | 29 |
| 2010 | 36 |
| 2011 | 61 |
| 2012 | 31 |
| 2013 | 45 |
| 2014 | 31 |
| 2015 | 16 |
| 2016 | 23 |
| 2017 | 24 |
| 2018 | 31 |
| 2019 | 19 |
| 2020 | 21 |
| 2021 | 22 |
| 2022 | 18 |
| 2023 | 10 |
| 2024 | 8 |
| 2025 | 8 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 573 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Alcon Research | 83 |
| Allergan | 47 |
| Glaukos Corporation | 27 |
| Aerie Pharmaceuticals | 18 |
| Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 13 |
| Santen Pharmaceutical Co., Ltd. | 12 |
| Wills Eye | 12 |
| Santen Inc. | 9 |
| Universitaire Ziekenhuizen KU Leuven | 8 |
| Aristotle University Of Thessaloniki | 7 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Glaucoma, Open-Angle | 573 |
| Ocular Hypertension | 323 |
| Glaucoma | 183 |
| Cataract | 22 |
| Exfoliation Syndrome | 15 |
| Hypertension | 15 |
| Low Tension Glaucoma | 15 |
| Eye Diseases | 12 |
| Glaucoma, Angle-Closure | 10 |
| Glaucoma, Neovascular | 7 |
Trials
Showing 1 to 25 of 573. Each trial links to its page on Pharma Observatory.
473 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.